Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Evolution of beta-lactamase inhibitors

D M Livermore1

  • 1London Hospital Medical College, Department of Medical Microbiology, England.

Intensive Care Medicine
|July 1, 1994
PubMed
Summary

Tazobactam extends the activity of piperacillin against many bacteria by inhibiting beta-lactamases. This combination therapy is effective against most common infections, though resistance can occur due to specific bacterial enzymes or altered targets.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Review of health economic models exploring and evaluating treatment and management of hospital-acquired pneumonia and ventilator-associated pneumonia.

The Journal of hospital infection·2020
Same author

The difficulties of identifying and treating Enterobacterales with OXA-48-like carbapenemases.

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases·2020
Same author

Evaluation of multiplex tandem PCR (MT-PCR) assays for the detection of bacterial resistance genes among Enterobacteriaceae in clinical urines.

The Journal of antimicrobial chemotherapy·2018
Same author

Re: "Comparison of antipseudomonal betalactams for febrile neutropenia empiric therapy: systematic review and network metaanalysis" by Horita et al.

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases·2018
Same author

Major role of pKpQIL-like plasmids in the early dissemination of KPC-type carbapenemases in the UK.

The Journal of antimicrobial chemotherapy·2017
Same author

Identification of bacterial pathogens and antimicrobial resistance directly from clinical urines by nanopore-based metagenomic sequencing.

The Journal of antimicrobial chemotherapy·2016

Area of Science:

  • Microbiology
  • Pharmacology
  • Infectious Diseases

Background:

  • Beta-lactamase enzymes pose a significant challenge to the efficacy of beta-lactam antibiotics like piperacillin.
  • Emerging resistance to beta-lactamase-stable cephalosporins necessitates alternative strategies, such as inhibitor combinations.
  • The effectiveness of beta-lactam/beta-lactamase inhibitor combinations is influenced by inhibitor efficiency, bacterial enzyme levels, drug properties, organism susceptibility, and environmental pH.

Purpose of the Study:

  • To evaluate the spectrum of activity and resistance patterns of piperacillin/tazobactam.
  • To assess the role of beta-lactamase inhibition in overcoming antibiotic resistance.
  • To review the clinical efficacy of piperacillin/tazobactam, particularly against challenging pathogens.

Main Methods:

  • Literature review and analysis of antimicrobial susceptibility data for piperacillin/tazobactam.
  • Assessment of beta-lactamase inhibition profiles of tazobactam against clinically relevant enzymes.
  • Evaluation of resistance mechanisms, including derepressed Class I beta-lactamases and altered penicillin-binding proteins.

Main Results:

  • Tazobactam effectively inhibits most clinically significant beta-lactamases, extending piperacillin's activity against Enterobacteriaceae, staphylococci, and anaerobes.
  • Resistance was observed in approximately 17% of Enterobacter, Citrobacter, and Serratia species, likely due to derepressed Class I beta-lactamases.
  • Piperacillin/tazobactam demonstrated broad-spectrum activity, with some questions regarding antistaphylococcal efficacy based on disc tests versus MICs, though clinical results were promising.

Conclusions:

  • Piperacillin/tazobactam combination therapy significantly broadens the antimicrobial spectrum of piperacillin, offering an effective strategy against many beta-lactamase-producing bacteria.
  • Resistance to piperacillin/tazobactam is primarily associated with specific beta-lactamase types or alterations in bacterial penicillin-binding proteins.
  • Clinical outcomes for staphylococcal infections treated with piperacillin/tazobactam appear favorable, supporting its use in selected cases.

Related Experiment Videos